Pfizer has hastened discussions with Allergan over a potential acquisition, according to reports.
Ireland-base Allergan confirmed at the end of last month it was in talks to join forces with its US rival, but according to a source close to the matter the decision making process has picked up pace.
Pfizer is said to be negotiating an offer of between $370 and $380 per Allergan share, valuing the company at $150bn. However, the source added a deal was far from certain following news that the US Treasury plans to tighten its tax evasion rules further. Both Allergan and Pfizer declined to comment.
Yet several details remain unresolved. Among them is whether the timing and structure of a takeover would be affected by new guidelines from the Treasury Department governing so-called corporate inversions, mergers in which the acquirer moves its headquarters to lower-tax jurisdictions abroad.
Late last month, the two companies confirmed that they were in preliminary talks.
Full content: The New York Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI